KEYNOTE-671: Neoadjuvant & Adjuvant Pembrolizumab in Early-Stage NSCLC – Phase 3 Trial Results.

2 Views
Published
This video highlights the pivotal results of the KEYNOTE-671 phase 3 trial, which evaluated neoadjuvant pembrolizumab plus chemotherapy followed by adjuvant pembrolizumab, versus neoadjuvant chemotherapy alone, in patients with resectable early-stage non-small-cell lung cancer (NSCLC).

???? Stay informed on major advancements in thoracic oncology.

#KEYNOTE671 #NSCLC #ImmunoOncology #LungCancerResearch #Pembrolizumab #CancerTrials
Category
Oncology
Be the first to comment